

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

## **ANNOUNCEMENT**

### **COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcements of Genscript Biotech Corporation (the “**Company**”) dated 14 May 2021 in relation to, among others, the issue of new shares under general mandate and the disposal of shares by a controlling shareholder and other related matters and clarifications, and the supplemental announcement of the Company dated 7 June 2021 in relation to the aforementioned announcements (collectively, the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

### **COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE**

The Board announces that all of the conditions of the Subscription Agreement have been fulfilled and that the completion of the Subscription under the Subscription Agreement took place on 10 June 2021. Accordingly, 102,981,853 Subscription Shares have been allotted and issued to the Investor at the Subscription Price of HK\$18.658 per Share pursuant to the terms and conditions of the Subscription Agreement.

Having deducted the fees and related expenses in connection with the issue of the Subscription Shares, the total amount of net proceeds received by the Company is approximately HK\$1,920.62 million. The Company intends to apply such net proceeds for general working capital of the Group, primary use in the research and development and expansion of manufacturing facilities, as well as general corporate expenses.

### **EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY**

The table below sets out a summary of the shareholding structure of the Company (i) before the completion of the Subscription; (ii) as at the date of this announcement, following the completion of the Subscription; (iii) after the completion of the Subscription and the Disposal (assuming there is no change in the issued share capital of the Company since the date of this announcement); and (iv)

after the completion of the Subscription and the Disposal (assuming there is no change in the issued share capital of the Company since the date of this announcement save for the issuance of the RSA Shares B).

Shareholders	Before the completion of the Subscription		As at the date of this announcement and following the completion of the Subscription		Immediately after this announcement and following the completion of the Subscription and the Disposal <sup>(Note2)</sup> (assuming there is no change in the issued share capital of the Company since the date of this announcement)		Immediately after this announcement and following the completion of the Subscription and the Disposal (assuming there is no change in the issued share capital of the Company since the date of this announcement save for the issuance of the RSA Shares B <sup>(Note3)</sup> )	
	<i>Number of</i>		<i>Number of</i>		<i>Number of</i>		<i>Number of</i>	
	<i>Shares held</i>	<i>%</i>	<i>Shares held</i>	<i>%</i>	<i>Shares held</i>	<i>%</i>	<i>Shares held</i>	<i>%</i>
Genscript Corporation <sup>(Note 1)</sup>	871,366,235	44.37	871,366,235	42.16	809,577,123	39.17	809,577,123	39.06
GNS Holdings Limited	—	—	102,981,853	4.98	164,770,965	7.97	164,770,965	7.95
Other shareholders	1,092,385,305	55.63	1,092,385,305	52.86	1,092,385,305	52.86	1,098,242,179	52.99
<b>Total issued Shares</b>	<b>1,963,751,540</b>	<b>100.00</b>	<b>2,066,733,393</b>	<b>100.00</b>	<b>2,066,733,393</b>	<b>100.00</b>	<b>2,072,590,267</b>	<b>100.00</b>

*Note:*

1. Genscript Corporation is a company incorporated in the State of Delaware in the U.S. and owned as to approximately 37.47%, approximately 3.66%, approximately 22.76%, approximately 7.96%, approximately 2.07%, approximately 0.70%, approximately 0.42%, approximately 0.42%, approximately 11.10%, approximately 10.26%, approximately 1.95%, approximately 1.05% and approximately 0.18% by Zhang Fangliang, the Zhang Trust, Wang Luquan, Wu Yongmei, the Wu 2017 Trust, the Wu 2019 Trust, the Wu 2020 Separate Trust A, the Wu 2020 Separate Trust B, the Wu 2020 Trust, Wang Ye, the Wang Trust, Mu Yingjun and Charity B, respectively.
2. As of the date of this announcement, the completion of the Disposal has not occurred.
3. For the issuance of the RSA Shares B, please refer to the announcement of the Company dated 1 June 2021 in relation to, among others, the issuance of the 5,856,874 RSA Shares B. As of the date of this announcement, such Shares have not been issued and allotted.

By order of the Board  
**GenScript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 10 June 2021

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* For identification purposes only